| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/14/2013 | US20130064881 Compositions and methods for treating prostate cancer |
| 03/14/2013 | US20130064880 Administration regime for n-hydroxy-4-benzamide |
| 03/14/2013 | US20130064879 Compositions and Methods for Inhibiting Viral Replication |
| 03/14/2013 | US20130064864 Submicron particles to decrease transfusion |
| 03/14/2013 | US20130064857 Methods and materials for making and using vaccines |
| 03/14/2013 | US20130064856 Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| 03/14/2013 | US20130064855 Reprogramming immune environment in breast cancer via dendritic cells |
| 03/14/2013 | US20130064840 Hjurp peptides and vaccines including the same |
| 03/14/2013 | US20130064838 Enhanced death receptor agonists |
| 03/14/2013 | US20130064837 Integrin alpha-v beta8 neutralizing antibody |
| 03/14/2013 | US20130064835 Rage regulates rock activity in cardiovascular disease |
| 03/14/2013 | US20130064833 Monitoring and Modulating HGF/HGFR Activity |
| 03/14/2013 | US20130064831 Immunotherapeutic dosing regimens and combinations thereof |
| 03/14/2013 | US20130064823 Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| 03/14/2013 | US20130064822 Humanized anti-egfl7 antibodies and methods using same |
| 03/14/2013 | US20130064821 Methods and compositions for treating prostate cancer |
| 03/14/2013 | US20130064818 Use of immunesuppressant receptor |
| 03/14/2013 | US20130064817 Engineered anti-il-23r antibodies |
| 03/14/2013 | US20130064815 Inducing apoptosis in quiescent cells |
| 03/14/2013 | US20130064814 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| 03/14/2013 | US20130064812 Combination therapies for hematologic malignancies |
| 03/14/2013 | US20130064811 Methods to Enhance Cancer Treatment |
| 03/14/2013 | US20130064810 Methods and Compositions for the Detection and Treatment of Cancer involving miRNAs and miRNA Inhibitors and Targets |
| 03/14/2013 | US20130064795 Immune modulation |
| 03/14/2013 | US20130064791 Interferon Analogs |
| 03/14/2013 | US20130064790 Peptides with the capacity to bind to interleukin-10 (il-10) |
| 03/14/2013 | US20130064789 Hairy Cell Leukemia Biomarkers and Methods of Using Same |
| 03/14/2013 | US20130064777 Surfactant-free water-free foamable compositions, breakable foams and gels their uses |
| 03/14/2013 | US20130064775 Use of riluzole for treating or preventing the adverse effects of antineoplastic agents |
| 03/14/2013 | US20130064761 Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof |
| 03/14/2013 | CA2848118A1 Endostatin mutants with mutations at atp binding sites |
| 03/14/2013 | CA2847907A1 Nanoparticle tumour vaccines |
| 03/14/2013 | CA2847837A1 A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate |
| 03/14/2013 | CA2847563A1 Amido compounds as ror.gamma.t modulators and uses thereof |
| 03/14/2013 | CA2847514A1 Amino-substituted imidazopyridazines |
| 03/14/2013 | CA2847114A1 Method for manufacturing block copolymer |
| 03/14/2013 | CA2847011A1 Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
| 03/14/2013 | CA2846884A1 Pharmaceutical compositions comprising an aromatase inhibitor |
| 03/14/2013 | CA2846676A1 Targeted liposomes in cancer therapy |
| 03/14/2013 | CA2846667A1 Serpinf2-binding molecules and methods of use |
| 03/14/2013 | CA2846372A1 Oncolytic herpes simplex virus and therapeutic uses thereof |
| 03/14/2013 | CA2846275A1 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| 03/14/2013 | CA2845380A1 Crystalline forms of cabazitaxel |
| 03/13/2013 | EP2567983A1 Tumor-targeted tumor necrosis factor-related apoptosis ligand variant and use thereof |
| 03/13/2013 | EP2567982A1 Antibody against carcinoembryonic antigen and uses thereof |
| 03/13/2013 | EP2567980A1 Use of neutralizing prolactin receptor antibodies for inhibition of lactation |
| 03/13/2013 | EP2567979A1 Use of neutralizing prolactin receptor antibodies for the treatment of hyper- and normoprolactinemic hair loss |
| 03/13/2013 | EP2567978A1 Use of neutralizing prolactin receptor antibodies for contraception |
| 03/13/2013 | EP2567977A1 Use of neutralizing prolactin receptor antibodies for the treatment of benign breast disease and mastalgia |
| 03/13/2013 | EP2567976A2 Antibodies against CD38 for treatment of multiple myeloma |
| 03/13/2013 | EP2567971A2 Peptide vaccines comprising Seq Id 80, 100 or 101 for cancers expressing tumor-associated antigens |
| 03/13/2013 | EP2567963A1 Trehalose compound, method for producing same, and pharmaceutical product containing the compound |
| 03/13/2013 | EP2567959A1 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| 03/13/2013 | EP2567956A1 Novel prenylarene compound and use thereof |
| 03/13/2013 | EP2567955A2 Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| 03/13/2013 | EP2567952A1 Cationic lipid |
| 03/13/2013 | EP2567951A1 Cationic lipid |
| 03/13/2013 | EP2567709A2 Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
| 03/13/2013 | EP2567707A2 Composition of tumour-associated peptides and related anti-cancer vaccine |
| 03/13/2013 | EP2567702A1 A particulate system comprising lanthanides for use in diminishing cell growth/inducing cell killing |
| 03/13/2013 | EP2566895A2 Anti-erbb3 antibodies |
| 03/13/2013 | EP2566894A1 Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| 03/13/2013 | EP2566893A1 Compositions and methods for the diagnosis and treatment of tumor |
| 03/13/2013 | EP2566892A1 Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| 03/13/2013 | EP2566876A1 Methods and compounds for inhibiting glycosyltransferases |
| 03/13/2013 | EP2566870A1 New pro-drugs of amaryllidaceae isocarbostyril products and their use against brain tumors |
| 03/13/2013 | EP2566869A1 Pyridone and aza-pyridone compounds and methods of use |
| 03/13/2013 | EP2566868A1 Pyrrolo [3, 2 -d]pyrimidin-3 -yl derivatives used as activators of ampk |
| 03/13/2013 | EP2566867A1 Pyrazole compounds as jak inhibitors |
| 03/13/2013 | EP2566861A1 Modulators of fatty acid amide hydrolase |
| 03/13/2013 | EP2566853A1 Tetrazolones as inhibitors of fatty acid synthase |
| 03/13/2013 | EP2566851A1 Combretastatin analogs for use in the treatment of cancer |
| 03/13/2013 | EP2566847A1 Novel immunomodulator and anti inflammatory compounds |
| 03/13/2013 | EP2566518A1 Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
| 03/13/2013 | EP2566509A1 Novel antibody to a carbonic anhydrase |
| 03/13/2013 | EP2566499A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| 03/13/2013 | EP2566496A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
| 03/13/2013 | EP2566495A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
| 03/13/2013 | EP2566482A1 Progesterone receptor antagonists and uses thereof |
| 03/13/2013 | EP2566480A2 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase |
| 03/13/2013 | EP2566479A1 Azaindazoles |
| 03/13/2013 | EP2566328A1 Indazoles |
| 03/13/2013 | EP2407536A9 ADP-ribosyl transferase fusion variant proteins |
| 03/13/2013 | EP1392359B2 Specific binding proteins and uses thereof |
| 03/13/2013 | CN1981776B Composition containing rare ginseng saponin, its production and usage |
| 03/13/2013 | CN102971340A Antibodies with enhanced or suppressed effector function |
| 03/13/2013 | CN102971336A Peptide for use as a medicament, in particular for the treatment of cancer |
| 03/13/2013 | CN102971330A Metal complexes of thiourea and their derivatives as metal delivering anti-cancer and anti-inflammatory agents |
| 03/13/2013 | CN102971329A Pyrrolobenzodiazepines used to treat proliferative diseases |
| 03/13/2013 | CN102971326A Imidazopyridazinyl compounds and their uses for cancer |
| 03/13/2013 | CN102971324A MTOR selective kinase inhibitors |
| 03/13/2013 | CN102971323A Heterocyclic compounds as JANUS kinase inhibitors |
| 03/13/2013 | CN102971321A Imidazopyrazines |
| 03/13/2013 | CN102971318A Tetrahydrocarboline derivative |
| 03/13/2013 | CN102971316A Fused bicyclic kinase inhibitors |
| 03/13/2013 | CN102971296A Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
| 03/13/2013 | CN102971293A Bipyridyl derivatives useful for the treatment of kinase-induced diseases |
| 03/13/2013 | CN102971011A Vaccine compositions based on sticholysin encapsulated in liposomes |
| 03/13/2013 | CN102971003A Improved cancer therapy based on tumor associated antigens derived from cyclin D1 |
| 03/13/2013 | CN102970989A Diclofenac salt of tramadol |